Alzheon
PrivateLast Round
Series B
Sep 10, 2026
Est. Valuation
$404.13M
Total Funding Raised
$260.9M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Alzheon is a biopharmaceutical company that develops a small molecule-based drug discovery platform aimed at treating Alzheimer's disease and other neurodegenerative disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B2C
Customer Profile
Hardware Sales, Government Contracts
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Alzheon Comparables
Compare Alzheon with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| AriBio | 81% | |
| Acumen Pharmaceuticals | 78% | |
| Annovis Bio, Inc. | 76% |
Alzheon Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Sep 10, 2026 | ||||
| Series E | Jun 12, 2024 | ||||
| Series D | Apr 14, 2022 | ||||
| Grant | Aug 20, 2020 | ||||
| Series C | Apr 24, 2019 | ||||
IPO | Jan 16, 2019 |
Key People
Founding team and executive leadership
Alzheon Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Ally Bridge Group | Convertible Debt, Series A, Series B |
| The Benchmark Company | IPO |
| H.C. Wainwright & Co. | IPO |
| National Institute on Aging | Grant |
| National Institute on Aging | Grant |
| ThinkEquity | IPO |
| Citigroup | IPO |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 10, 2026
$79M round raised
- Mar 21, 2026
Presented new biomarker data for oral anti-amyloid therapy at AD/PD 2026.
Alzheon Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Alzheon's valuation, stock price, and market status.
Is Alzheon a public or private company?
Alzheon is a private company.
What is the current stock price of Alzheon?
Alzheon is a private company with no public stock price. No recent secondary market data is available.
How much is Alzheon worth (valuation)?
Alzheon's valuation is estimated at $404.1M based on funding round data.
Can I buy Alzheon stock?
Alzheon shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Alzheon's last funding round?
Alzheon's most recent funding round was Series E on April 24, 2019.
Who are the main investors in Alzheon?
Key investors in Alzheon include Ally Bridge Group.
Will Alzheon IPO soon?
No public IPO plans have been announced for Alzheon.
How can I track Alzheon secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Alzheon's secondary market activity and sign up for updates.